View Older Stories View More Recent Stories
-
Doximity Inc (DOCS) PT Lowered to $26 at Mizuho
-
Doximity Inc (DOCS) PT Lowered to $30 at Canaccord
-
Raymond James Downgrades Doximity Inc (DOCS) to Outperform, 'Valuation Case Still Attractive'
-
BTIG Downgrades Doximity Inc (DOCS) to Neutral
-
Doximity Inc (DOCS) PT Lowered to $19 at Evercore ISI
-
Doximity Inc (DOCS) PT Lowered to $27 at Needham
-
Doximity Inc (DOCS) PT Lowered to $19 at Truist Securities
-
Baird Downgrades Doximity Inc (DOCS) to Neutral
-
Jefferies Downgrades Doximity Inc (DOCS) to Hold
-
KeyBanc Downgrades Doximity Inc (DOCS) to Sector Weight
-
Wells Fargo Downgrades Doximity Inc (DOCS) to Equal Weight
-
After-hours movers: CSCO, HPE, DOCS, STUB, STAA, GO
-
Doximity integrates AI tools with Aledade's care platform
-
Doximity, Inc. (DOCS) Misses Q4 EPS by 2c, Beats on Revenue; Offers FY26 Revenue Guidance
-
BTIG highlights key trends from Boston Digital Health Summit
-
Raymond James on Doximity Inc (DOCS): 'We don’t view the news positively'
-
Raymond James Reiterates Strong Buy Rating on Doximity Inc (DOCS)
-
Doximity Inc (DOCS) PT Raised to $34 at Leerink Partners
-
Truist Securities Downgrades Doximity Inc (DOCS) to Hold
-
Doximity Inc (DOCS) PT Lowered to $47 at BofA Securities, 'Some incremental positives against market concerns'
-
Evercore ISI Downgrades Doximity Inc (DOCS) to In Line
-
Freedom Capital Markets Starts Doximity Inc (DOCS) at Buy
-
Doximity Inc (DOCS) PT Raised to $42 at Piper Sandler
-
Which healthcare stocks are at risk from AI and which to buy
-
Doximity Inc (DOCS) PT Lowered to $34 at Mizuho
-
Canaccord Genuity Upgrades Doximity Inc (DOCS) to Buy
-
Canaccord Genuity Upgrades Doximity Inc (DOCS) to Buy
-
Investor overreaction is a buying opportunity in this MedTech stock: Morgan Stanley
-
Doximity Inc (DOCS) PT Lowered to $25 at BMO Capital Amid Near-Term Headwinds
-
Doximity Inc (DOCS) PT Lowered to $37 at Truist Securities
-
Doximity Inc (DOCS) PT Lowered to $55 at Needham
-
Doximity Inc (DOCS) PT Lowered to $40 at Piper Sandler
-
JPMorgan Upgrades Doximity Inc (DOCS) to Neutral
-
After-hours movers: Amazon, Roblox, Bloom Energy, Reddit, Molina Health and more
-
Doximity, Inc. (DOCS) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
-
Doximity Inc (DOCS) PT Lowered to $70 at BofA Securities
-
Goldman Sachs Upgrades Doximity Inc (DOCS) to Buy
-
Raymond James on Doximity Inc (DOCS): 'We likely aren’t done with the competitive dynamic narrative'
-
RBC Capital Starts Doximity Inc (DOCS) at Outperform
-
Raymond James comments on Doximity, Inc. (DOCS) post webinar: 'The expert hasn’t seen any changes to budgets for DTC spending'
-
Truist Securities Upgrades Doximity Inc (DOCS) to Buy
-
Evercore ISI on Doximity Inc (DOCS): 'we expect Doximity to remain the anchor professional and commercial platform'
-
This software stock has a 'Strong Buy' rating at Raymond James
-
Doximity settles securities lawsuit for $31 million
-
Raymond James on Doximity Inc (DOCS): 'We would continue to buy shares on the recent pullback'
-
Piper are buyers of 'these high quality, profitable, growth' stocks
-
Piper Sandler: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch'
-
BofA Securities on Doximity Inc (DOCS): 'No shift from DTC, but HCP growth is accelerating'
-
Piper: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch in Boston'
-
Morgan Stanley Upgrades Doximity Inc (DOCS) to Overweight

